JSMC-10396

THE OUTCOME OF SARS-COV2 INFECTION AMONG CHILDREN WITH CANCER IN SULAIMANIYAH PROVINCE, IRAQ

Khanda Muhammed Abdulla a, Khalid Hama Salih a, and Bakir Rahim Rashid a

Submitted: 15/8/2022; Accepted: 12/11/2022; Published: 21/3/2023

a College of Medicine-University of Sulaimani, Kurdistan Region, Iraq.

DOI Link: https://doi.org/10.17656/jsmc.10396 

---------------------------------------------------------------------------------------------------------------------------------------------------------------

ABSTRACT

Background 

The most significant and pervasive health issue faced the globe during the last 2years was coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Patients diagnosed with childhood cancer may have impaired immune systems due to their illness or therapy, increasing their vulnerability to COVID-19 infection.

Objectives 

To determine the outcome of COVID-19 in children with malignancy who received chemotherapy, explain characteristic features, and assess the severity of COVID-19 among haematological vs oncological malignancies

Patients and Methods

This Retro-prospective cohort study was carried out in the Hiwa oncology Hospital in the Sulaimaniyah governorate from November 2021 to February 2022 on 70 children with cancer using PCR to confirm their COVID-19 infection (60 haematological cases and ten oncological cases).

Results

Among the total 70 patients involved in the study, 52.9% were males, 47.1% were females, and their mean age was 8.83 ± 4.3. About sixty-two (90%) cases had haematological malignancies, and 8(10%) had oncological malignancies. The most predominant symptom was fever (82.9%), followed by cough (67.1%). On the other hand, 58 (82.9%) cases had mild disease, and 8 (11.4%) had the moderate disease. Chest x-ray infiltration was found in 12 (17.1%) cases; 14 (20.0%) children needed hospital admission, only 1 (1.4%) case required intensive care unit (ICU) admission, and 6 (8.6%) patients needed O2 therapy. Sixty-seven children recovered from COVID-19, and three children died. 

Conclusion

Most children with cancer (CwC) had mild infections and were outpatients with benign outcomes. Haematological malignancies, especially acute lymphoblastic leukaemia (ALL), are the commonest malignancies among COVID-19 patients. Most COVID-19 patients were symptomatic, with fever and cough being the predominant symptoms.

KEYWORDS

Children, COVID-19, SARS-CoV 2, Malignancy, Hiwa Hospital.

References 

1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54. 

2. Kumar M, al Khodor S. Pathophysiology and treatment strategies for COVID-19. J Transl Med. 2020;18(1):1–9. 

3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine. 2020 March 26;382(13):1199–207. 

4. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical immunology. 2020; 215:108427. 

5. Madhusoodhan PP, Pierro J, Musante J, Kothari P, Gampel B, Appel B, et al. Characterization of COVID-19 disease in pediatric oncology patients: the New York-New Jersey regional experience. Pediatr Blood Cancer. 2021;68(3):e28843. 

6. Zare-Zardini H, Soltaninejad H, Ferdosian F, Hamidieh AA, Memarpoor-Yazdi M. Coronavirus disease 2019 (COVID-19) in children: prevalence, diagnosis, clinical symptoms, and treatment. Int J Gen Med. 2020; 13:477. 

7. Cristiani L, Mancino E, Matera L, Nenna R, Pierangeli A, Scagnolari C, et al. Will children reveal their secrets? The coronavirus dilemma. European Respiratory Journal. European Respiratory Society; 2020;55(4): 1–1. 

8. Kahn AR, Schwalm CM, Wolfson JA, Levine JM, Johnston EE. COVID-19 in Children with Cancer. Curr Oncol Rep. 2022;1–8. 

9. Tolunay O, Çelik Ü, Arslan I, Tutun B, Özkaya M. Evaluation of Clinical Findings and Treatment Results of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Center Experience. Front Pediatr. (2022). March 10;10. 

10. Arous R, Djillali IS, Rouis NO, Boudiaf H, Amhis W, Ziane H, et al. High mortality of COVID-19 in children with cancer in a single centre in Algiers, Algeria. Pediatric Blood and Cancer. John Wiley and Sons Inc; 2021;68(6): 1–2. 

11. Mukkada S, Bhakta N, Chantada GL, Chen Y, Vedaraju Y, Faughnan L, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021;22(10):1416–26. 

12. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, Juárez-Villegas L, Márquez-González H. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2021;3103. 

13. Sankar J, Dhochak N, Kabra SK, Lodha R. COVID-19 in Children: Clinical Approach and Management. Indian Journal of Pediatrics. Springer; 2020;87: 433–42. 

14. Amicucci M, Mastronuzzi A, Ciaralli I, Piccioni F, Schiopu AC, Tiozzo E, et al. Managing children with cancer during the covid-19 pandemic: A rapid review. J Clin Med. 2020 Nov 1;9(11):1–15. 

15. Ebeid F, ragab iman, Elsherif nayera, Makkeyah S, Mostafa S, Eltonbary K, et al. COVID-19 in Children with Cancer: A single Low-Middle income centre experience. 2020; 43(8):e1077-e1081

16. Al-Asadi JN, Ibrahim SJ. Childhood cancer in Basrah, Iraq during 2012-2016: Incidence and mortality. Asian Pacific Journal of Cancer Prevention. 2018 August 1;19(8):2337–41. 

17. Jawass MA, Al-Ezzi JI, Gouth HSB, Bahwal SA, Bamatraf FF, Ba’amer AA. The pattern of malignancies in children <15 years of age was reported in Hadhramout Cancer Registry, Yemen, between 2002 and 2014. Saudi Med J. 2016 May 1;37(5):513–20. 

18. Hammad M, Shalaby L, Sidhom I, Sherief N, Abdo I, Soliman S, et al. Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country. Clin Lymphoma Myeloma Leuk. 2021 Nov 1;21(11):e853–64. 

19. Leibel SL, Sun X. Covid-19 in early life: Infants and children are affected too. Physiology. American Physiological Society; 2021; 36(6):359–66. 

20. Choi JH, Choi SH, Yun KW. Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis. J Korean Med Sci. 2022;37(5). 

21. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. international incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017 June 1;18(6):719–31. 

22. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020 October 1;21(10):1309–16. 

23. de Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brandão MB. Clinical manifestations of children with COVID-19: a systematic review. Pediatr Pulmonol. 2020;55(8):1892–9. 

24. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine. 2020 July 1;24. 

25. Salih AF, Hamasalih K, Rahman HS, Mohammed GA. Pediatric COVID-19 infection in Sulaimaniyah Governorate, Iraq. American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 2022 January 1;43(1). 

26. Pandrowala A, Panchal H, Mudaliar S, Bodhanwala M, Prabhu S, Jain S, et al. SARS-CoV-2-related multisystem inflammatory syndrome in an immunocompromised child with leukaemia. Pediatric Blood and Cancer. John Wiley and Sons Inc; 2021;68(7):1-1

27. Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, et al. Risk Factors for Severe COVID-19 in Children. Pediatric Infectious Disease Journal. 2021; E137–45.

Full Text